Literature DB >> 6732213

Pharmacokinetics of vancomycin in patients with various degrees of renal function.

G R Matzke, R W McGory, C E Halstenson, W F Keane.   

Abstract

The pharmacokinetics of vancomycin were characterized in 56 patients with different degrees of renal function after an intravenous dose of 18.4 +/- 4.7 mg kg-1 (mean +/- standard deviation). Seven subjects had a creatinine clearance (CLCR) of greater than 60 ml min-1 (group I), 13 had a CLCR of 10 to 60 ml min-1 (group II), and 36 had a CLCR of less than 10 ml min-1 (group III). Serial serum samples (range, 3 to 8) were collected during the 168 h after drug administration. The serum concentration-time profile in all patients demonstrated monoexponential decay. The mean half-lives were 9.1, 32.3, and 146.7 h in groups I, II, and III, respectively. A significant decline in serum clearance (CLS) was also noted (62.7 to 28.3 to 4.87 ml min-1 in groups I, II, and III, respectively). The steady-state volume of distribution varied from 0.72 to 0.90 liter kg-1. There was no significant relationship between the steady-state volume of distribution and CLCR. The observed relationship between CLS and CLCR (CLS = 3.66 + 0.689 CLCR; r = 0.8807) can be utilized to devise dosage schedules for patients with any degree of renal impairment. This relationship was utilized to develop a nomogram for initial and maintenance dosing of vancomycin.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732213      PMCID: PMC185546          DOI: 10.1128/AAC.25.4.433

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Renal excretion of vancomycinin in kidney disease.

Authors:  H E Nielsen; H E Hansen; B Korsager; P E Skov
Journal:  Acta Med Scand       Date:  1975-04

3.  Prevention of staphylococcal shunt infections by continuous vancomycin prophylaxis.

Authors:  A J Morris; R T Bilinsky
Journal:  Am J Med Sci       Date:  1971-08       Impact factor: 2.378

4.  Peritoneal transport of vancomycin during peritoneal dialysis.

Authors:  H E Nielsen; I Sørensen; H E Hansen
Journal:  Nephron       Date:  1979       Impact factor: 2.847

5.  Dosage of vancomycin.

Authors:  J G Gambertoglio; W R Wilson; R E Van Scoy
Journal:  Mayo Clin Proc       Date:  1978-03       Impact factor: 7.616

6.  Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations.

Authors:  J C Rotschafer; K Crossley; D E Zaske; K Mead; R J Sawchuk; L D Solem
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

7.  Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis.

Authors:  D D Lindholm; J S Murray
Journal:  N Engl J Med       Date:  1966-05-12       Impact factor: 91.245

8.  Vancomycin.

Authors:  J E Geraci; P E Hermans
Journal:  Mayo Clin Proc       Date:  1983-02       Impact factor: 7.616

9.  Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis.

Authors:  S Eykyn; I Phillips; J Evans
Journal:  Br Med J       Date:  1970-07-11

10.  Vancomycin therapy in patients with impaired renal function: a nomogram for dosage.

Authors:  R C Moellering; D J Krogstad; D J Greenblatt
Journal:  Ann Intern Med       Date:  1981-03       Impact factor: 25.391

  10 in total
  80 in total

1.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

2.  Vancomycin in Pediatric Patients with Solid or Hematological Malignant Disease: Predictive Performance of a Population Pharmacokinetic Model and New Optimized Dosing Regimens.

Authors:  Amélie Marsot; F Gallais; C Galambrun; C Coze; O Blin; N Andre; R Guilhaumou
Journal:  Paediatr Drugs       Date:  2018-08       Impact factor: 3.022

Review 3.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma.

Authors:  T G Cantú; J D Dick; D E Elliott; R L Humphrey; D M Kornhauser
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

5.  Comparison of methods for estimating glomerular filtration rate in critically ill patients with acute kidney injury.

Authors:  Josée Bouchard; Etienne Macedo; Sharon Soroko; Glenn M Chertow; Jonathan Himmelfarb; Talat Alp Ikizler; Emil P Paganini; Ravindra L Mehta
Journal:  Nephrol Dial Transplant       Date:  2009-08-13       Impact factor: 5.992

6.  Comparison of the effects of three haemodialysis membranes on vancomycin disposition.

Authors:  J Alwakeel; T A Najjar; M J al-Yamani; S Huraib; A al-Haider; H Abu-aisha
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

Review 7.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

8.  Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.

Authors:  Adam Frymoyer; Adam L Hersh; Leslie Z Benet; B Joseph Guglielmo
Journal:  Pediatr Infect Dis J       Date:  2009-05       Impact factor: 2.129

Review 9.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

10.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.